Effect of AKT inhibition on epithelial-mesenchymal transition and ZEB1-potentiated radiotherapy in nasopharyngeal carcinoma

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1234-1240

  Chen, Weiguo ^a   Wu, Sipei ^b   Zhang, Gong ^c   Wang, Wenjun ^b   Shi, Yongsheng ^b  

^a Pingxiang People's Hospital   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c People Hospital of Shanxi Province   (China)

Author keywords

AKT kinase inhibitor; AKT ZEB1 pathway; Epithelial mesenchymal transition; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

4 [2 (4 AMINO 1, 2, 5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO [4, 5 C] PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CLINICAL ARTICLE; COLONY FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE RISK; SURVIVAL RATE; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84884470740     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1552     Document Type: Article

References (31)

1. Erkal HS, Serin M and Cakmak A: Nasopharyngeal carcinomas: analysis of patient, tumor and treatment characteristics determining outcome. Radiother Oncol61: 247-256, 2001.
2. Roychowdhury DF, Tseng A Jr, Fu KK, Weinburg V and WeidnerN: New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer77: 1419-1426, 1996.
3. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC and WangAY: Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol33: 501-508, 2003.
4. Geara FB, Glisson BS, Sanguineti G, et al: Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer79: 1279-1286, 1997.
5. Sanguineti G, Geara FB, Garden AS, et al: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys37: 985-996, 1997.
6. Yeh SA, Tang Y, Lui CC, Huang YJ and Huang EY: Treatment outcomes and late complications of 849patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys62: 672-679, 2005.
7. Wei WH, Cai XY, Xu T, et al: Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stageIII and IVA-B nasopharyngeal carcinoma. Asian Pac J Cancer Prev13: 785-789, 2012.
8. Nijkamp MM, Span PN, Hoogsteen IJ, van der Kogel AJ, KaandersJH and Bussink J: Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol99: 344-348, 2011.
9. Kang Y and Massagué J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell118: 277-279, 2004.
10. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell139: 871-890, 2009.
11. Zhou YC, Liu JY, Li J, et al: Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition. Int J Radiat Oncol Biol Phys81: 1530-1537, 2011.
12. Theys J, Jutten B, Habets R, et al: E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol99: 392-397, 2011.
13. Liu Y, Chen LH, Yuan YW, Li QS, Sun AM and Guan J: Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumour Biol33: 241-245, 2012.
14. Castaneda CA, Cortes-Funes H, Gomez HL and Ciruelos EM: The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev29: 751-759, 2010.
15. Bussink J, van der Kogel AJ and Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol9: 288-296, 2008.
16. Rhodes N, Heerding DA, Duckett DR, et al: Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res68: 2366-2374, 2008.
17. Altomare DA, Zhang L, Deng J, et al: GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res16: 486-496, 2010.
18. Heerding DA, Rhodes N, Leber JD, Clark TJ, et al: Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)3-piperidinylmethyl]oxy}1H-imidazo[4,5-c]pyridin-4-yl)2-methyl-3-butyn2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem51: 5663-5679, 2008.
19. Andarawewa KL, Erickson AC, Chou WS, et al: Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res67: 8662-8670, 2007.
20. Li T, Zeng ZC, Wang L, et al: Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther18: 617-626, 2011.
21. Santisteban M, Reiman JM, Asiedu MK, et al: Immune-induced epithelial to mesenchymal transition invivo generates breast cancer stem cells. Cancer Res69: 2887-2895, 2009.
22. Fernandez-L A, Squatrito M, Northcott P, et al: Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene31: 1923-1937, 2012.
23. Carol H, Morton CL, Gorlick R, et al: Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer55: 1329-1337, 2010.
24. Wang J, Guo LP, Chen LZ, Zeng YX and Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res67: 3716-3724, 2007.
25. von Essen CF: Radiation enhancement of metastasis: a review. Clin Exp Metastasis9: 77-104, 1991.
26. Jeong JW, Jin CY, Park C, et al: Inhibition of migration and invasion of LNCaP human prostate carcinoma cells by cordycepin through inactivation of Akt. Int J Oncol40: 1697-1704, 2012.
27. Setsu N, Yamamoto H, Kohashi K, et al: The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer118: 1637-1648, 2012.
28. Radisky DC: Epithelial-mesenchymal transition. J Cell Sci118: 4325-4326, 2005.
29. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al: Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells27: 2059-2068, 2009.
30. Tanno S, Yanagawa N, Habiro A, et al: Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res64: 3486-3490, 2004.
31. Li HF, Kim JS and Waldman T: Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol4: 43, 2009.